ALD
Hanau am Main, Germany
ALD
Hanau am Main, Germany

Time filter

Source Type

WASHINGTON, DC--(Marketwired - Feb 14, 2017) - The National Academies of Sciences, Engineering and Medicine today issued a report that examines the scientific, clinical, ethical, legal and social implications of human genome editing. The Alliance for Regenerative Medicine (ARM) believes that genomic medicines, including genome editing, hold great promise for the treatment of a multitude of hereditary and acquired diseases where there is presently no effective treatment available. The Alliance for Regenerative Medicine (ARM) applauds the National Academies of Sciences, Engineering and Medicine for its very thorough and thoughtful report on the current scientific, technical, ethical, and policy issues relating to human genome editing. We support the need for responsible and ethically appropriate approaches to research and clinical use of these technologies following the seven guiding principles outlined in the report, as well as the need for continued public engagement and dialogue. We also commend the Academies for recognizing the profound impact genome editing will have on the development of a new class of medicines for many patients with presently incurable diseases. We believe the report's recommendations that "existing regulatory infrastructure and processes for reviewing and evaluating somatic gene therapy to treat or prevent disease and disability" are sensible and will help create a safe path toward eventual clinical adoption and regulatory approval of therapeutics based on somatic cell genome editing. In addition, we note the report's recommendations on heritable germline genome editing and the strict criteria to be met before ever considering clinical study. ARM will continue to monitor developments related to these applications, but until safety is proven and the risks associated with long-term consequences, both intended and unintended, are fully evaluated, we will remain solely focused on realizing the full therapeutic potential of somatic cell genome editing. Further, we must be satisfied that all relevant moral and ethical issues have been addressed and that a broad societal consensus exists as to the benefits and risks associated with editing the germline. ARM believes that advances in the field of gene therapy, including somatic cell genome editing, have the potential to profoundly and positively impact the practice of medicine for currently incurable genetic diseases, such as muscular dystrophy, sickle cell disease (SCD), cystic fibrosis, hemophilia, adrenoleukodystrophy (ALD), Alpha-1 Antitrypsis Deficiency (AATD), and Transthyretin Amyloidosis (ATTR), as well as acquired diseases such as cancer, certain forms of heart disease, HIV, Hepatitis B virus, and other infectious diseases. It is estimated that 30 million Americans, or 1 in every 10 people, are afflicted with one of the approximately 7,000 rare diseases. Two thirds of those affected are children. The National Organization for Rare Disorders (NORD) estimates that for 95 percent of these diseases no FDA-approved treatment currently exists,(1) and the few treatments that are available generally address the symptoms and not the underlying genetic cause of the disease. As a result, these treatments must be administered for the duration of a patient's life. In contrast, genome editing offers the very real potential to bring hope to rare disease patients through development of a broad range of new technologies to precisely target and modify the genetic material of a patient's cells. By removing, repairing, or replacing a defective gene or genes, these therapies hold the promise of potentially curing a broad range of diseases with a single treatment. Similarly, in diseases such as cancer, HIV, and beta-thalessemia, genome editing is being employed to modify T cells and hematopoietic stem cells ex-vivo. The modified cells are then delivered to the patient to treat and potentially cure the underlying disease. These programs build upon early successes and several advanced programs based on somatic cell gene replacement therapies. According to a recent white paper titled, "Therapeutic Gene Editing," published by the American Society of Gene & Cell Therapy (ASGCT), "the successful development of effective treatments based on genome editing could shift today's approach from a lifetime of symptom management for hereditary diseases to tomorrow's ideal of making a one-time curative repair or change to an individual's affected gene. The goal is a long lasting, perhaps life-long effect that minimizes or even eliminates disease."(2) Diseases involving multiple genes may also be treatable if the therapy can alter specific genes affecting the course of the disease. ARM represents a number of companies and research institutions that use various gene therapy and genome editing technology platforms, including CRISPR/Cas9, zinc finger nucleases (ZFNs), homing endonucleases, vector-driven homologous recombination, transcription activator-like effector-based nucleases (TALEN) and meganucleases, amongst others to design therapeutics that address a wide range of, hereditary and acquired diseases. About The Alliance for Regenerative Medicine The Alliance for Regenerative Medicine (ARM) is an international multi-stakeholder advocacy organization that promotes legislative, regulatory and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine worldwide. ARM also works to increase public understanding of the field and its potential to transform human healthcare, providing business development and investor outreach services to support the growth of its member companies and research organizations. Prior to the formation of ARM in 2009, there was no advocacy organization operating in Washington, D.C. to specifically represent the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today, ARM has more than 250 members and is the leading global advocacy organization in this field. To learn more about ARM or to become a member, visit http://www.alliancerm.org. 1. National Organization for Rare Disorders (2015). NORD developing 20 natural history studies for 20 rare diseases (Press Release). https://rarediseases.org/fda-awards-nord-250000-grant-to-support-the-development-of-20-natural-history-studies-for-rare- disease-research/. 2. American Society of Gene & Cell Therapy (2016). Therapeutic Gene Editing: An American Society of Gene & Cell Therapy White Paper. http://www.asgct.org/UserFiles/file/TherapeuticGeneEditingWP_Nov21_v1.pdf.


Research and Markets has announced the addition of the "The Nanocoatings Global Opportunity Report" report to their offering. 'The Nanocoatings Global Opportunity Report' examines a market that is already providing significant economic, hygiene and environmental benefit for sectors such as consumer electronics, construction, medicine & healthcare, textiles, oil & gas, infrastructure and aviation. Research and development in nanotechnology and nanomaterials is now translating into tangible consumer products, providing new functionalities and opportunities in industries such as electronics, sporting goods, wearable electronics, textiles, construction etc. A recent example is quantum dot TVs, a multi-billion dollar boon for the High-definition TV market. Countless other opportunities exist for exploiting the exceptional properties of nanomaterials and these will increase as costs come down and production technologies improve. The incorporation of nanomaterials into thin films, coatings and surfaces leads to new functionalities, completely innovative characteristics and the possibility to achieve multi-functional coatings and smart coatings. The use of nanomaterials also results in performance enhancements in wear, corrosion-wear, fatigue and corrosion resistant coatings. Nanocoatings demonstrate significant enhancement in outdoor durability and vastly improved hardness and flexibility compared to traditional coatings. - Oil and gas - - Corrosion and scaling chemical inhibitors. - - Self-healing coatings. - - Smart coatings. - - Coatings for hydraulic fracturing. - Aerospace & aviation - - Shape memory coatings. - - Corrosion resistant coatings for aircraft parts. - - Thermal protection. - - Novel functional coatings for prevention of ice-accretion and insect-contamination. - Renewable energy - - Anti-fouling protective coatings for offshore marine structures. - - Anti-reflective solar module coatings. - - Ice-phobic wind turbines. - - Coatings for solar heating and cooling. - Automotive - - Anti-fogging nanocoatings and surface treatments. - - Improved mar and scratch resistance. - - Flexible glass. - - Corrosion prevention. - - Multi-functional glazing. - - Smart surfaces. - - Surface texturing technologies with enhanced gloss. - - New decorative and optical films. - - Self-healing. - Textiles & Apparel - - Sustainable coatings. - - High UV protection. - - Smart textiles. - - Electrically conductive textiles. - - Enhanced durability and protection. - - Anti-bacterial and self-cleaning. - - Water repellent while maintaining breathability.. - Medical - - Hydrophilic lubricious, hemocompatible, and drug delivery coatings. - - Anti-bacterial coatings to prevent bacterial adhesion and biofilm formation. - - Hydrophobic and super-hydrophobic coatings. - - Lubricant coatings. - - Protective implant coatings. - - High hardness coatings for medical implants. - - Infection control. - - Antimicrobial protection or biocidic activity. - Marine - - Anti-fouling and corrosion control coatings systems. - - Reduced friction coatings. - - Underwater hull coatings. - Buildings - - Thermochromic smart windows. - - Anti-reflection glazing. - - Self-cleaning surfaces. - - Passive cooling surfaces. - - Air-purifying. - Consumer electronics - - Waterproof electronic devices. - - Anti-fingerprint touchscreens. - Global market size for target markets - Addressable markets for nanocoatings, by nanocoatings type and industry - Estimated market revenues for nanocoatings to 2025 - 300 company profiles including products and target markets 1 Executive Summary 1.1 High performance coatings 1.2 Nanocoatings 1.3 Market drivers and trends 1.4 Market size and opportunity 1.5 Market and technical challenges 2 Introduction 2.1 Properties of nanomaterials 2.2 Categorization 2.3 Nanocoatings 2.4 Hydrophobic coatings and surfaces 2.5 Superhydrophobic coatings and surfaces 2.6 Oleophobic and omniphobic coatings and surfaces 6 Market Segment Analysis, By Coatings Type 6.1 Anti-Fingerprint Nanocoatings 6.2 Anti-Microbial Nanocoatings 6.3 Anti-Corrosion Nanocoatings 6.4 Abrasion & Wear-Resistant Nanocoatings 6.5 Barrier Nanocoatings 6.6 Anti-Fouling And Easy-To-Clean Nanocoatings 6.7 Self-Cleaning (Bionic) Nanocoatings 6.8 Self-Cleaning (Photocatalytic) Nanocoatings 6.9 Uv-Resistant Nanocoatings 6.10 Thermal Barrier And Flame Retardant Nanocoatings 6.11 Anti-Icing And De-Icing 6.12 Anti-Reflective Nanocoatings 6.13 Other Nanocoatings Types 7 Market Segment Analysis, By End User Market 7.1 Aerospace 7.2 Automotive 7.3 Construction, Architecture And Exterior Protection 7.4 Electronics 7.5 Household Care, Sanitary And Indoor Air Quality 7.6 Marine 7.7 Medical & Healthcare 7.8 Military And Defence 7.9 Packaging 7.10 Textiles And Apparel 7.11 Renewable Energy 7.12 Oil And Gas Exploration 7.13 Tools And Manufacturing 7.14 Anti-Counterfeiting - 3M - Abrisa Technologies - Accucoat, inc - Aculon, Inc - Acreo Engineering - ACTNano, inc - Advanced Materials-JTJ S.R.O - Advanced Silicon Group - Advenira Enterprises, Inc - Aeonclad Coatings - agPolymer S.r.l - Agienic Antimicrobials - Agion Technologies, Inc - AkzoNobel - Albert Rechtenbacher GmbH - ALD Nanosolutions, Inc - Alexium, Inc - AM Coatings - Analytical Services & Materials, Inc - Ancatt - Applied Nanocoatings, Inc - Applied Nano Surfaces - Applied Sciences, Inc - Applied Thin Films, Inc - ARA-Authentic GmbH - Asahi Glass Co., Ltd - Autonomic Materials - Aurolab - Avaluxe International GmbH - Bactiguard AB - BASF Corporation - Battelle - Beijing ChamGo Nano-Tech Co., Ltd., - Beneq OY - BigSky Technologies LLC - Biocote Ltd - Bio-Gate AG - Bioni CS GmbH - Bionic Technology Holding BV - Boral Limited - Buhler Partec - BYK-Chemie GmbH - California Nanotechnologies Corporation - Cambridge Nanotherm Limited - Cambrios Technologies Corporation - Canatu Oy - Carbodeon Ltd. Oy - Ceko Co., Ltd - Cellutech AB - CeNano GmbH & Co. KG - Cellmat Technologies S.L - Centrosolar Glas GmbH Co. KG - Cetelon Nanotechhnik GmbH - CG2 Nanocoatings, Inc - Cima Nanotech - Clarcor Industrial Air - Clariant Produkte (Deutschland) GmbH - Cleancorp Nanocoatings - Clearbridge Technologies Pte. Ltd - Clearjet Ltd - Clou - CMR Coatings GmbH - CNM Technologies GmbH - Coating Suisse GmbH - Corning, Incorporated - Cotec GmbH - Coval Molecular Coatings - Crossroads Coatings - CSD Nano, Inc - CTC Nanotechnology GmbH - C3 Nano - Cytonix CLLC - Daicel FineChem Limited - Daikin Industries, ltd - Diamon-Fusion International, Inc - Diarc-Technology Oy - DFE Chemie GmbH - Dow Corning - Dropwise Technologies Corporation - DryWired - Dry Surface Technologies LLC - DSP Co., Ltd - Duralar Technologies - Duraseal Coatings - Eeonyx Corporation - Eikos, Inc - Engineered Nanoproducts Germany AG - Enki Technology - Envaerospace, Inc - Eurama Corporation - Europlasma NV - Excel Coatings - Evonik Hanse - Few Chemicals GmbH - FN Nano, Inc - ForgeNano - Formacoat - Fujifilm - Fumin - FutureCarbon GmbH - Future Nanocoatings - General Paints - Green Earth nano Science, Inc - Green Millenium, Inc - Grenoble INP-Pagora - Grupo Repol - GSI Creos - GVD Corporation - GXC Coatings - Hanita Coatings - Hardide Coatings - HeiQ Materials AG - Hemoteq GmbH - Henkel AG & Co. KGaA - Hexis S.A - Hiab Products - Hitachi Chemical - Honeywell International, Inc - Hy-Power Nano, Inc - HzO, Inc - Hygratek, LLC - iFyber, LLC - Imbed Biosciences, Inc - Imerys - Industrial Nanotech, Inc - Inframat Corporation - INM - Leibniz Institute for New Materials - InMat, Inc - InMold Biosystems - Innovcoat Nanocoatings and Surface Technologies Inc - Inno-X - Innventia AB - Inspiraz Technology pte LTd - Instrumental Polymer Technologies LLC - Ishihara Sangyo Kaisha, Ltd - Integrated Surface Technologies, Inc - Integran Technologies, Inc - Integricote - Interlotus Nanotechnologie GmbH - Intumescents Associates Group - ISTN, Inc - ISurTech - ITN Nanovation AG - Izovac Ltd - JNC Corporation - Joma International AS - Jotun Protective Coatings - Kaneka Corporation - Klockner Pentaplast Europe GmbH & Co. KG - Kon Corporation - Kriya Materials B.V - Laiyang Zixilai Environment Protection Technology Co., Ltd - Life Air Iaq Ltd - Lintec of America, Inc., - Liquiglide, Inc - Liquipel, LLC - Lofec Nanocoatings - Lotus Applied Technology - Lotus Leaf Coatings - Luna Innovtions - Magnolia Solar - MDS Coating Technologies Corporation - Melodea - Merck Performance Materials - Mesocoat, Inc - Metal Estalki - Millidyne Oy - MMT Textiles Limited - Modumetal, Inc - Molecular Rebar - Muschert - N2 Biomedical - Naco Technologies, Inc - Nadico Technologie GmbH - Nagase & Co - Nanohygienix LLC - Namos GmbH - Nanobiomatters S.I - Nano-care AG - NanoCover A/S - Nanocure GmbH - Nanocyl - Nanofilm, Ltd - Nano Frontier Technology - Nanoex Company - Nanogate AG - Nanohmics - Nanohorizons, Inc - Nanokote Pty Ltd - Nanomate Technology - Nano Labs Corporation - NanoLotus Scandanavia Aps - Nanomembrane - NanoPack, Inc - NanoPhos SA - Nanopool GmbH - Nanops - Nanoservices BV - Nanoshell Ltd - Nanosol AG - Nanosonic, Inc - The NanoSteel Company, Inc - Nano Surface Solutions - NanoSys GmbH - Nanotech Security Corporation - Nano-Tex, Inc - NanoTouch Materials, LLC - Nanovere Technologies, LLC - Nanovis Incorporated - Nanoveu Pte. LTD - Nanowave Co., Ltd - Nano-X GmbH - Nanoyo Group Pte Ltd - Nanto Protective Coating - NBD Nano - NEI Corporation - Nelum Sciences LLC - Nelumbo - Neverwet LLC - NGimat - NIL Technology ApS - Nissan Chemical Industries Ltd - NOF Corporation - NTC Nanotech Coatings GmbH - n-tec GmbH - NTT Advanced Technology Corporation - Oceanit - Opticote Inc - Optics Balzers Ag - Optitune International Pte - Organiclick AB - Oxford Advanced SUrfaces - P2i Ltd - Panahome Corporation - Percenta AG - Perpetual Technologies, Inc - Philippi-Hagenbuch, Inc - Picosun Oy - Pioneer Medical Devices GmbH - Pneumaticicoat Technologies - PJI Contract Pte Ltd - Polymerplus, LLC - Powdermet, Inc - PPG Industries - Promimic AB - Pureti, Inc - Quantiam Technologies, Inc, - RBNano - Reactive Surfaces, LLP - Resodyn Corporation - Rochling Engineering Plastics - Royal DSM N.V - Saint-Gobain Glass - Sandvik Materials Technology - Sarastro GmbH - Schott AG - Seashell Technology LLC-Hydrobead - Semblant - Shandong Huimin Science & Technology Co., Ltd - Sharklet Technologies, Inc - Shin-Etsu Silicones - SHM - Sioen Industries NV - SiO2 Nanotech, LLC - Sketch Co., Ltd - Slips Technology - Sono-Tek Corporation - Spartan Nano Ltd - Starfire Systems, inc - Sub-One Technology, INc - Sumitomo Electric Hard-Metal Ltd - Suncoat GmbH - SupraPolix BV - SurfaceSolutions GmbH - Surfactis Technologies SAS - Surfatek LLC - Surfix BV - Suzhou Super Nano-Textile Teco Co - Takenake Seisakusho Co., Ltd - Tesla Nanocoatings - Theta Coatings - TNO - TopChim NV - Topasol LLC - Toray Advanced Film Co., Ltd - Toto - TripleO Performance Solution - Ultratech International, Inc - Vadlau GmbH - Valentis Nanotech - Vestagen Protective Technologies, Inc - Viriflex - VTT Technical Research Center - Wacker Chemie AG - Wattglass, LLC - Well Shield LLC - Zschimmer & Schwarz For more information about this report visit http://www.researchandmarkets.com/research/4ktr5t/the_nanocoatings Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.


News Article | March 1, 2017
Site: cen.acs.org

Researchers have identified a small organic molecule that may help fix the genetic defect that causes X-linked adrenoleukodystrophy (X-ALD), the rare disease featured in the 1992 movie “Lorenzo’s Oil.” X-ALD, which affects 1 in 20,000 to 50,000 people worldwide, typically kills boys diagnosed in early childhood, and an adult form impairs nervous system function progressively. The underlying problem is an inherited mutation in the gene for ABCD1, a protein that transports very-long-chain fatty acids (VLCFAs) to units inside cells called peroxisomes, which break them down. The mutation allows VLCFAs to overaccumulate in the brain and spinal cord, where they destroy myelin sheaths on brain and spinal cord nerve cells by an unknown mechanism. Director of chemical biology Thomas S. Scanlan and coworkers at Oregon Health & Science University show that sobetirome, a small molecule they discovered earlier, reduces VLCFA levels in the brains of X-ALD mice (Endocrinology 2017, DOI: 10.1210/en.2016-1842). The compound works by activating the gene that makes ABCD2, a close relative of ABCD1 that does not contain an inherited mutation, partially restoring normal VLCFA breakdown. As depicted in the movie, the parents of Lorenzo Odone, who was six when diagnosed with X-ALD, discovered Lorenzo’s Oil, an extract of rapeseed and olive oils that inhibits VLCFA synthesis. The product is available commercially but is still experimental. Lorenzo lived much longer than expected but died at age 30. Several drug candidates have tried to boost expression of the gene for ABCD2, but none has been successful. Scanlan and coworkers hope sobetirome, an orally administered compound that activates the thyroid hormone receptor and can reach the brain, might do better. After oral dosing for 12 weeks, it lowered brain VLCFAs 15 to 20% in X-ALD mice. Is that sufficient to be therapeutic? Only clinical trials will tell. Sobetirome caused few side effects in an earlier human clinical trial for cholesterol lowering. NeuroVia, in Cambridge, Mass., which Scanlan helped found, is developing sobetirome clinically to treat X-ALD, and the Food & Drug Administration has given the compound orphan-drug status, which provides development incentives such as tax credits. Stephane Savary of the University of Bourgogne, who cloned the gene for ABCD2 and studied the in vitro effects of sobetirome on expression of the gene, comments that the study’s “results in mice are really encouraging and deserve a clinical trial.”


News Article | March 2, 2017
Site: globenewswire.com

ASM International N.V. (Euronext Amsterdam: ASM) today reports its fourth quarter 2016 operating results (unaudited) in accordance with IFRS. With the 2015 Q4 earnings release, published on February 23, 2016, ASMI announced that as of January 1, 2016, it will report its financial results in accordance with IFRS. Up until the last reporting regarding 2015, ASMI's primary external and internal reporting has been based on US GAAP. In addition ASMI issued quarterly reconciliations of net earnings and shareholders' equity and statutory interim reports prepared in accordance with International Financial Reporting Standards (IFRS). Following the voluntary delisting from NASDAQ, August 2015, ASMI migrated to IFRS as its only internal and external reporting standard from January 1, 2016, and discontinued the use of US GAAP as of the same date. During 2016 comparable results based on US GAAP were presented; as from 2017 results based on IFRS only will be reported. The main deviations between IFRS and US GAAP are explained in Annex 2. ·      Net sales for the fourth quarter 2016 were €173 million, an increase of 20% compared to the previous quarter. Year-on-year net sales increased with 19%. ·     New orders at €177 million were 44% above the Q3 2016 level. ·     Normalized net earnings for the fourth quarter 2016 increased by €29 million compared to the third quarter 2016. Operating result increased to €30 million. The financing result included €19 million positive effects from currencies compared to €3 million negative effects in the third quarter. The result from investments decreased with €8 million. Commenting on the results, Chuck del Prado, President and Chief Executive Officer of ASM International said: "The strong overall market climate for semiconductor equipment towards the end of 2016 led to better sales and a higher order intake for Q4 than forecasted. The net cash position of ASMI remained strong. In addition to a stable proposed dividend of €0.70 per share, we announce today an increase in our current share buyback program from € 50 million to €100 million." We continue to expect a clear improvement in the single wafer ALD market in 2017: We expect that the single wafer ALD market experienced a double digit decline in 2016. Based upon that we forecast the single wafer ALD market to reach a size of approx. US$1.5 billion in 2020-2021. We project a year-on-year sales increase for the first half of 2017, whereby we expect a sales level of €135-145 million for Q1 and €160-200 million for Q2, both on a currency comparable level. The order intake in Q1 is expected to remain healthy at a level of €170-190 million, also on a currency comparable level. On October 26, 2016, ASMI announced a share buyback program for the repurchase of up to €50 million of the Company's common shares within the 2016-2017 time frame. Today, ASMI announces that its Management Board authorized an increase in this program to €100 million. On May 25, 2016, the Annual General Meeting of Shareholders authorized ASMI to acquire shares for a period of 18 months. The repurchase program is part of ASMI's commitment to use excess cash for the benefit of its shareholders. The program started on December 13, 2016. On December 31, 2016, 12.9% of the program was completed at an average share price of €42.31. At the end of 2016 ASMI held 3.98 million treasury shares, which is more than sufficient to cover our outstanding options and restricted/performance shares. Hence ASMI will propose to the Annual General Meeting, to be held on May 22, 2017, to cancel 1.5 million treasury shares. In December 2016, ASMI finalized the renewal of the current standby revolving credit facility. The security of the previous credit agreement has been released. The maturity date of the new credit commitment of €150 million is December 16, 2021, with an extension option for up to two years. As per December 31, 2016, this facility was undrawn. The credit facility of €150 million includes two financial covenants: These financial covenants are measured twice each year, on June 30 and December 31. We were in compliance with these financial covenants as per December 31, 2016. ASM International NV, headquartered in Almere, the Netherlands, its subsidiaries and participations design and manufacture equipment and materials used to produce semiconductor devices. ASM International, its subsidiaries and participations provide production solutions for wafer processing (Front-end segment) as well as for assembly & packaging and surface mount technology (Back-end segment) through facilities in the United States, Europe, Japan and Asia. ASM International's common stock trades on the Euronext Amsterdam Stock Exchange (symbol ASM). For more information, visit ASMI's website at . Cautionary Note Regarding Forward-Looking Statements: All matters discussed in this press release, except for any historical data, are forward-looking statements. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. These include, but are not limited to, economic conditions and trends in the semiconductor industry generally and the timing of the industry cycles specifically, currency fluctuations, corporate transactions, financing and liquidity matters, the success of restructurings, the timing of significant orders, market acceptance of new products, competitive factors, litigation involving intellectual property, shareholders or other issues, commercial and economic disruption due to natural disasters, terrorist activity, armed conflict or political instability, epidemics and other risks indicated in the Company's reports and financial statements. The Company assumes no obligation nor intends to update or revise any forward-looking statements to reflect future developments or circumstances. ASM International will host an investor conference call and web cast on Friday, March 03, 2017 at 15:00 Continental European Time (9:00 a.m. - US Eastern Time). The teleconference dial-in numbers are as follows: A simultaneous audio webcast and replay will be accessible at .


News Article | March 1, 2017
Site: globenewswire.com

ASM International has received a supplier excellence award as one of five equipment suppliers from TSMC for the performance and support of ASM's ALD equipment and technology during 2016. The award was presented to ASM by TSMC Co-Chief Executive Officer, Dr. Mark Liu, at the TSMC Supply Chain Management Forum on February 23, 2017 in Taiwan. The award was received by ASM in recognition of its ALD technology and performance in production at TSMC fabs. During the presentation, TSMC explained three points that contributed to the award to ASM. 1)     Cutting-edge tool innovations for advanced nodes. 2)     Superb support to achieve quick solutions on consigned tools. 3)     Great record of on-time tool delivery. "We are very honored to receive this prestigious award from TSMC and thank TSMC for this recognition," said Chuck del Prado, CEO and President of ASM International, "ASM highly values our partnership with TSMC and we are very pleased that our Pulsar ALD and Eagle XP8 PEALD tools have provided strong benefits to TSMC in its production fabs." TSMC is the world's largest semiconductor manufacturing foundry. TSMC hosts the Supply Chain Management forum annually to show appreciation for the support and contributions of its suppliers and to recognize outstanding equipment and materials suppliers. ASM International NV, headquartered in Almere, the Netherlands, its subsidiaries and participations design and manufacture equipment and materials used to produce semiconductor devices. ASM International, its subsidiaries and participations provide production solutions for wafer processing (Front-end segment) as well as for assembly & packaging and surface mount technology (Back-end segment) through facilities in the United States, Europe, Japan and Asia. ASM International's common stock trades on the Euronext Amsterdam Stock Exchange (symbol ASM). For more information, visit ASMI's website at . Cautionary Note Regarding Forward-Looking Statements: All matters discussed in this press release, except for any historical data, are forward-looking statements. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. These include, but are not limited to, economic conditions and trends in the semiconductor industry generally and the timing of the industry cycles specifically, currency fluctuations, corporate transactions, financing and liquidity matters, the success of restructurings, the timing of significant orders, market acceptance of new products, competitive factors, litigation involving intellectual property, shareholders or other issues, commercial and economic disruption due to natural disasters, terrorist activity, armed conflict or political instability, epidemics and other risks indicated in the Company's reports and financial statements. The Company assumes no obligation nor intends to update or revise any forward-looking statements to reflect future developments or circumstances.


News Article | February 17, 2017
Site: www.cemag.us

The Fraunhofer Institute for Process Engineering and Packaging IVV, together with the Fraunhofer Institute for Applied Polymer Research IAP and the Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB, have developed new developments in films and the efficient control of coating processes. The development of a cost-effective, optical measuring system means that coating processes will in the future be able to be fully controlled and monitored over the entire substrate surface. The degree of crosslinking and thickness of organic coatings can be controlled inline via automated coupling of the measurement system to the coating unit. This prevents issues such as delamination, poor processing of web-shaped materials, and increased migration of non-crosslinked adhesive components. High-barrier laminates manufactured in roll-to-roll processes for the encapsulation of flexible solar cells and electronic components must have as low as possible oxygen and water vapor permeability. For quality assurance, it is a challenge to measure the permeability of such films over long periods of time. The tests can take several months. Now, however, the Fraunhofer IVV has developed a device for measuring the permeability of ultra barrier films in combination with associated computer software for simulating the permeation process. This enables the water vapor permeability to be determined 3 to 4 times faster than with conventional methods. The Fraunhofer IVV has acquired a new coating plant which utilizes atomic layer deposition to further reduce the permeability of films. Minimizing the permeability to water vapor and oxygen is the key to successful further improvement of high barrier films. Atomic layer deposition (ALD) is paving the way here. Coating via roll-to-roll processes allows high processing speeds and production efficiency to be achieved. Up until now, films with the highest barriers have been produced exclusively in vacuum processes. The new ALD plant at the Fraunhofer IVV enables the barrier properties of films to be significantly improved. This is a further step towards meeting the permeability requirements for OLED encapsulation in the medium term. The Fraunhofer IVV is using this technology for publicly funded R&D projects and to provide industry with customized solutions and research services for the development of processes and materials. The formation of ice on the rotor blades of wind turbines results in aerodynamic imbalance. In order to prevent damage, either the rotor blades must be heated or the wind turbine must be shut down. To tackle this issue, the Fraunhofer IGB has developed a number of anti-icing coatings suitable for polymer surfaces. These water-repelling microstructured and nanostructured coatings ensure that any water remains a liquid, even at temperatures below zero, resulting in a 90 percent reduction in ice adhesion compared to uncoated surfaces. The trick: The surfaces provide the water molecules with no crystallization nuclei. Plasma technology is used to deposit the structured coatings onto plastic films made of impact-resistant polyurethane (PU). The coatings are not only of interest for wind turbines: these functional surfaces can also be applied to aircraft wings and solar panels. Furthermore, anti-icing coatings can also be directly applied to fabrics and plastics, for example for winter sports clothing, tents, and other outdoor articles. Regardless of whether the requirement is for anti-fouling and easy-to-clean surfaces, printable films, or eco-friendly water-repelling textiles, the Fraunhofer IGB usually uses plasma processes to create these new surface properties. Plasma processes allow the top layers to be removed, so generating pristine surfaces and enabling chemical functionalities or other layers to be applied. Selection and control of the chemical processes enable the scientists at the Fraunhofer IGB to customize the surface energy and hence the wetting properties. This enables even textiles to be effectively equipped with water-repelling or oil-repelling properties — in an eco-friendly way without harmful byproducts or waste products. Whilst the properties of most synthetic materials are fixed, many biological systems have the ability to adapt to changing environmental conditions. Materials are, however, now being developed with properties which "change" on exposure to external stimuli. These so-called "intelligent" materials change, for example, when exposed to various physical and chemical stimuli such as temperature, light intensity, and pH or due to biomolecules such as proteins. This is being achieved using special polymers developed by the Fraunhofer IAP. This development work is being supported by surface technologies which allow even these intelligent materials to be manufactured on a large scale in roll-to-roll processes. In addition to classical methods such as corona and plasma treatment, printing methods (entire surface or structured) are widely used for the functionalization of surfaces.


SAN JOSE, Calif., Feb. 16, 2017 /PRNewswire/ -- Ultratech, Inc. (Nasdaq: UTEK), a leading supplier of lithography, laser­ processing and inspection systems used to manufacture semiconductor devices and high-brightness LEDs (HBLEDs), as well as atomic layer deposition (ALD) systems, today...


News Article | February 21, 2017
Site: www.marketwired.com

PLAINVIEW, NY and SAN JOSE, CA--(Marketwired - February 21, 2017) - Veeco Instruments Inc. ( : VECO), a global leader of advanced thin film etch and deposition process equipment, and Ultratech, Inc. ( : UTEK), a leading supplier of lithography, laser-processing and inspection systems used to manufacture semiconductor devices and LEDs, today announced that, on February 17, 2017, Veeco Instruments Inc. ("Veeco") and Ultratech, Inc. ("Ultratech") received notice from the U.S. Federal Trade Commission that it had granted early termination, effective immediately, of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) for Veeco's pending acquisition of Ultratech. The early termination of the waiting period under the HSR Act satisfies one of the conditions to the closing of the transaction. The transaction is expected to close in second calendar quarter of 2017, subject to approval by Ultratech shareholders as well as other closing conditions. About Veeco Veeco's process equipment solutions enable the manufacture of LEDs, displays, power electronics, compound semiconductors, hard disk drives, semiconductors, MEMS and wireless chips. We are the leader in MOCVD, MBE, Ion Beam, Wet Etch single wafer processing and other advanced thin film process technologies. Our high performance systems drive innovation in energy efficiency, consumer electronics and network storage and allow our customers to maximize productivity and achieve lower cost of ownership. For information on our company, products and worldwide service and support, please visit www.Veeco.com. About Ultratech Ultratech designs, builds and markets manufacturing systems for the global technology industry. Founded in 1979, Ultratech serves three core markets: frontend semiconductor, backend semiconductor, and nanotechnology. The company is the leading supplier of lithography products for bump packaging of integrated circuits and high-brightness LEDs. Ultratech is also the market leader and pioneer of LSA technology for the production of advanced semiconductor devices. In addition, the company offers solutions leveraging its proprietary CGS technology to the semiconductor wafer inspection market and provides ALD tools to leading research organizations, including academic and industrial institutions. Visit Ultratech online at: www.Ultratech.com. Additional Information and Where to Find It In connection with the proposed acquisition of Ultratech, by Veeco pursuant to the terms of an Agreement and Plan of Merger by and among Ultratech, Veeco and Ulysses Acquisition Subsidiary Corp. ("Merger Sub"), Veeco will file with the Securities and Exchange Commission (the "SEC") a Registration Statement on Form S-4 (the "Form S-4") that will contain a proxy statement of Ultratech and a prospectus of Veeco, which proxy statement/prospectus will be mailed or otherwise disseminated to Ultratech's stockholders when it becomes available. Investors are urged to read the proxy statement/prospectus (including all amendments and supplements) because they will contain important information. Investors may obtain free copies of the proxy statement/prospectus when it becomes available, as well as other filings containing information about Veeco and Ultratech, without charge, at the SEC's Internet site (http://www.sec.gov). Copies of these documents may also be obtained for free from the companies' web sites at www.Veeco.com or www.Ultratech.com. Participants in Solicitation Veeco, Ultratech and their respective officers and directors may be deemed to be participants in the solicitation of proxies from the stockholders of Ultratech in connection with the proposed transaction. Information about Veeco's executive officers and directors is set forth in its Annual Report on Form 10-K, which was filed with the SEC on February 25, 2016 and its proxy statement for its 2016 annual meeting of stockholders, which was filed with the SEC on March 22, 2016. Information about Ultratech's executive officers and directors is set forth in its Annual Report on Form 10-K, which was filed with the SEC on February 26, 2016, Amendment No. 1 to its Annual Report on Form 10-K, which was filed with the SEC on April 22, 2016, and the proxy statements for its 2016 annual meeting of stockholders, which were filed with the SEC on June 10, 2016 and June 13, 2016. Investors may obtain more detailed information regarding the direct and indirect interests of the Veeco, Ultratech and their respective executive officers and directors in the acquisition by reading the preliminary and definitive proxy statement/prospectus regarding the transaction, which will be filed with the SEC. Forward-Looking Statements This written communication contains forward-looking statements that involve risks and uncertainties concerning Veeco's proposed acquisition of Ultratech, Ultratech's and Veeco's expected financial performance, as well as Ultratech's and Veeco's strategic and operational plans. Actual events or results may differ materially from those described in this written communication due to a number of risks and uncertainties. The potential risks and uncertainties include, among others, the possibility that Ultratech may be unable to obtain required stockholder approval or that other conditions to closing the transaction may not be satisfied, such that the transaction will not close or that the closing may be delayed; the reaction of customers to the transaction; general economic conditions; the transaction may involve unexpected costs, liabilities or delays; risks that the transaction disrupts current plans and operations of the parties to the transaction; the ability to recognize the benefits of the transaction; the amount of the costs, fees, expenses and charges related to the transaction and the actual terms of any financings that will be obtained for the transaction; the outcome of any legal proceedings related to the transaction; the occurrence of any event, change or other circumstances that could give rise to the termination of the transaction agreement. In addition, please refer to the documents that Veeco and Ultratech file with the SEC on Forms 10-K, 10-Q and 8-K. The filings by Veeco and Ultratech identify and address other important factors that could cause its financial and operational results to differ materially from those contained in the forward-looking statements set forth in this written communication. All forward-looking statements speak only as of the date of this written communication nor, in the case of any document incorporated by reference, the date of that document. Neither Veeco nor Ultratech is under any duty to update any of the forward-looking statements after the date of this written communication to conform to actual results.


Home > Press > Strem Chemicals and Dotz Nano Ltd. Sign Distribution Agreement for Graphene Quantum Dots Collaboration Abstract: Strem Chemicals, Inc., a manufacturer of specialty chemicals for research and development, and Dotz Nano Ltd., an exciting new company aimed at capitalizing on the technological innovation in the Graphene Quantum Dots (GQD) market, are proud to announce the signing of a licensing agreement. With this agreement in place, Strem Chemicals will become a global distributor of Graphene Quantum Dots. Dotz Nano Ltd. uses low-cost, raw material to make high-quality and cost-effective products. These products can be used in various applications, such as medical imaging, sensing, consumer electronics, energy storage, solar cells, and computer storage. “Strem is excited to introduce this unique line of products, especially at a time when the graphene market is growing steadily. Graphene Quantum Dots can be used for a wide variety of applications and partnering with Dotz Nano Ltd. will allow us to offer this new technology to our customers.” said Dr. Ephraim S. Honig, Chief Executive Officer at Strem. Commenting on the new agreement, Dotz Nano’s CEO, Dr. Moti Gross, stated “The marketing and sales agreement which Dotz Nano has signed with Strem Chemicals will allow Dotz, through Strem, to supply and service a large group of valuable consumers that usually are either in research, pilot production phase or other types of activities. This agreement will allow Dotz Nano to take advantage of Strem’s marketing and logistics systems.” About Strem Chemicals, Inc. Strem Chemicals, Inc., established in 1964, is a privately held manufacturer and marketer of specialty chemicals of high purity. Strem’s key products include catalysts, ligands, organometallics, metal carbonyls, CVD/ALD precursors and nanomaterials. Its products are used for research and development and commercial scale applications, especially in the pharmaceutical, microelectronics, chemicals and petrochemicals industries. Strem Chemicals also provides custom synthesis, process development and cGMP manufacturing services. Strem is an ISO 9001 certified company. For more information, visit www.strem.com. Dotz Nano Ltd. Dotz Nano Limited (ASX: DTZ) is a technology company focusing on the development, manufacture and commercialization of graphene quantum dots (GQDs). Its vision is to be the premier producer of GQDs by producing and supplying high quality GQDs for use in various applications including medical imaging, sensing, consumer electronics, energy storage, solar cells and computer storage. To learn more about Dotz Nano please view the website and our corporate video via the following link: www.dotznano.com For more information, please click If you have a comment, please us. Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.


News Article | February 15, 2017
Site: www.prweb.com

Given the growing demands placed on the electrical, optical and thermal functionality of LEDs, engineers are paying more and more attention to the advancement of new material properties. To this end, the FLINGO project (Functional Inorganic Layers for Next Generation Optical Devices) was established to develop new materials (layers, in particular) and processes to improve the efficiency and durability of LEDs. As the project coordinator, Osram Opto Semiconductors is working with renowned universities, research institutes and companies to maintain and improve market leadership in innovative LED products. The German Federal Ministry for Education and Research is sponsoring the FLINGO project – set to run through January 2020 – as part of the M-ERA.NET EU initiative, an EU-financed network set up to support the coordination of European research projects. In the FLINGO project, researchers will investigate and combine different deposition methods for thin films such as atomic layer deposition, spray pyrolysis and the sol gel process for manufacturing high-quality LED light sources. Under the leadership of Dr. David O’Brien from Osram Opto Semiconductors, the project partners will be working on the entire bandwidth of new component properties – including extended lifetime, smaller electrical layer resistance and improved light extraction. These require new materials and innovative or adapted deposition processes. “The project objectives can only be achieved with the assistance of a broad-based consortium because they call for improvements, new developments and especially expert know-how across the entire value added chain,” explained O’Brien. Interdisciplinary expertise from five project partners The members of the FLINGO project in addition to Osram Opto Semiconductors are: Uninova from the New University of Lisbon; the Finnish thin film technology company Picosun Oy; the Fraunhofer Institute for Silicate Research ISC in Würzburg; and Vilnius University. Fraunhofer ISC provides support with its proficiency in the development of new inorganic layer systems which are to be used as the matrix for sensitive converter materials. Uninova adds its expertise in the manufacture of highly transparent and highly conductive layers which are needed for the p-contact in the LEDs. Picosun Oy is developing atomic layer deposition (ALD) processes and new materials to ensure conformal coating of even heavily structured surfaces. The Institute for Applied Research at Vilnius University provides specialist knowledge in the development and characterization of non-destructive material properties and will analyze the new layers and layer systems developed in the FLINGO project. As an end user of the technologies developed in FLINGO, Osram Opto Semiconductors will ultimately transfer the new thin layers and layer systems to its LEDs to test them for their suitability for the mass market. “The results of the project should lead to highly efficient and durable white light LEDs with possible applications in general lighting for example,” added O’Brien. “Our intention here is to improve our competitiveness and that of European industry in this field.” ABOUT OSRAM OSRAM, based in Munich, is a globally leading lighting manufacturer with a history dating back about 100 years. The product portfolio includes high-tech applications based on semiconductor technology such as infrared or laser lighting. The products are used in highly diverse applications ranging from virtual reality, autonomous driving or mobile phones to smart and connected lighting solutions in buildings and cities. In automotive lighting, the company is the global market and technology leader. Based on continuing operations (excluding Ledvance), OSRAM had around 24,600 employees worldwide at the end of fiscal 2016 (September 30) and generated revenue of almost €3.8 billion in that fiscal year. The company is listed on the stock exchanges in Frankfurt and Munich (ISIN: DE000LED4000; WKN: LED400; trading symbol: OSR). Additional information can be found at http://www.osram.com.

Loading ALD collaborators
Loading ALD collaborators